# A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC

> **NCT07334483** · PHASE2 · RECRUITING · sponsor: **GrandPharma (China) Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- HCC

## Interventions

- **DRUG:** Yttrium [90Y] Microsphere Injection
- **OTHER:** Conventional transcatheter arterial chemoembolization
- **DRUG:** Camrelizumab
- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT07334483
- **Lead sponsor:** GrandPharma (China) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-22
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07334483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07334483, "A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07334483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*